中药单体抗腹膜纤维化的研究进展  

Research Progress of Chinese Medicine Monomer Resistance of Peritoneal Fibrosis

作　　者：刘盼英 杨康 杨洪涛[1] LIU Panying;YANG Kang;YANG Hongtao(The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300380,China)

机构地区：[1]天津中医药大学第一附属医院,天津300380

出　　处：《中华中医药学刊》2020年第11期190-193,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金面上项目(81673909)。

摘　　要：腹膜纤维化(peritoneal fibrosis,PF)是长期腹膜透析(peritoneal dialysis,PD)患者的常见并发症,可以导致腹膜超滤功能减退与转运功能衰竭,腹膜的结构和功能丧失。在较大程度上制约了患者腹膜透析的顺利进行,最终成为患者退出PD的主要原因。通过阅读近年来国内外PD相关文献,分析中药抗腹膜纤维化的单体有效成分。常用中药单体包括黄芪甲苷、丹参酮ⅡA、川芎嗪、白芍总苷、苦参碱、大黄素、三七总皂苷、甘草酸二胺、灯盏花素等。从中药单体抗腹膜纤维化研究进展概况出发,阐述其相应的作用机制,以求为中药单体抗腹膜纤维化的相关研究提供参考。Peritoneal fibrosis(PF) is a common complication of long-term peritoneal dialysis(PD), which can lead to the decrease of peritoneal ultrafiltration function and transport failure, peritoneal structure and loss of function. It restricts the smooth progress of peritoneal dialysis and even becomes the main reason for patients to withdraw from PD. In this paper, the effective monomer components of traditional Chinese medicine against peritoneal fibrosis were analyzed by reading the literature related to PD at home and abroad in recent years. Commonly-used traditional Chinese medicine monomers included astragaloside IV, tanshinone IIA, ligustrazine, total glucosides of paeony, matrine, emodin, total saponins of panax notoginseng, diammonium glycyrrhizinate, breviscapine, etc. Based on the research progress of anti-peritoneal fibrosis of TCM monomer, the corresponding mechanism of action was expounded in order to provide reference for the related research of anti-peritoneal fibrosis of TCM monomer.

关 键 词：腹膜纤维化 中药单体 研究进展 

分 类 号：R259.722[医药卫生—中西医结合]